624729-66-4

Basic information

• Product Name: 8-Amino-1,2,3,4-tetrahydro-2-naphthol
• Synonyms: 8-Amino-1,2,3,4-tetrahydro-2-naphthol;4-tetrahydro-;8-aMino-1;8-aMino-1,2,3,4-tetrahydronaphthalen-2-ol
• CAS NO: 624729-66-4
• Molecular Formula: C₁₀H₁₃NO
• Molecular Weight: 163.22
• Mol File: 624729-66-4.mol

Chemical Properties

• Boiling Point: 347.1 °C at 760 mmHg
• Flash Point: 163.7 °C
• Appearance: /
• Density: 1.204
• Vapor Pressure: 2.07E-05mmHg at 25°C
• Refractive Index: 1.64
• PKA: 14.72±0.20(Predicted)
• CAS DataBase Reference: 8-Amino-1,2,3,4-tetrahydro-2-naphthol(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Amino-1,2,3,4-tetrahydro-2-naphthol(624729-66-4)
• EPA Substance Registry System: 8-Amino-1,2,3,4-tetrahydro-2-naphthol(624729-66-4)

Safety Data

• Hazardous Substances Data: 624729-66-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
8-Amino-1,2,3,4-tetrahydro-2-naphthol is used as a reagent in organic synthesis for its ability to participate in various chemical reactions, contributing to the formation of complex organic molecules.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 8-Amino-1,2,3,4-tetrahydro-2-naphthol is used as a key intermediate in the synthesis of various drugs, leveraging its unique chemical structure to create therapeutically relevant compounds.
Used in Agrochemical Production:
8-Amino-1,2,3,4-tetrahydro-2-naphthol is also utilized in the agrochemical sector, where it serves as a precursor in the development of pesticides and other agricultural chemicals, enhancing crop protection and yield.
Used in Research Applications:
8-Amino-1,2,3,4-tetrahydro-2-naphthol is employed in research settings for the investigation of new chemical reactions and the development of novel synthetic pathways, further expanding its utility in the scientific community.

InChI:InChI=1/C10H13NO/c11-10-3-1-2-7-4-5-8(12)6-9(7)10/h1-3,8,12H,4-6,11H2

Upstream product

• 118-46-7 8-amino-2-naphthol 
• 444619-84-5 8-bromo-1,2,3,4-tetrahydronaphthalen-2-ol 
• 117294-21-0 8-bromo-2-tetralone 
• 624729-65-3 (7-ethoxy-5,8-dihydronaphthalen-1-yl)amine 
• 1254716-32-9 tert-butyl N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)carbamate 
• 624729-74-4 8-amino-3,4-dihydronaphthalen-2(1H)-one 

Downstream Products

• 711016-23-8 2-(3-bromophenyl)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 
• 912957-55-2 8-(6-(2-Amino-4-(trifluoromethyl)phenyl)pyrimidin-4-ylamino)-1,2,3,4-tetrahydronaphthalen-2-ol 
• 711016-15-8 3',4'-difluoro-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)biphenyl-4-carboxamide 
• 711015-38-2 N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-(4'-methylbiphenyl-3-yl)urea 
• 711016-20-5 2-biphenyl-3-yl-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 
• 710954-91-9 N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[3-piperidin-1-yl-4-(trifluoromethyl)benzyl]urea 
• 1146695-97-7 8-{[5-(4-bromophenyl)-4-ethyl-1,3-oxazol-2-yl]amino}-1,2,3,4-tetrahydronaphthalen-2-ol 
• 1146695-94-4 8-({4-ethyl-5-[2-fluoro-4-(trifluoromethyl)phenyl]-1,3-oxazol-2-yl}amino)-1,2,3,4-tetrahydronaphthalen-2-ol 
• 1146695-91-1 8-({5-[3-chloro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-oxazol-2-yl}amino)-1,2,3,4-tetrahydronaphthalen-2-ol 
• 1146695-72-8 8-{[5-(4-chloro-3-fluorophenyl)-4-methyl-1,3-oxazol-2-yl]amino}-1,2,3,4-tetrahydronaphthalen-2-ol 
• 1146695-69-3 8-{[5-(4-cyclopropyl-3-fluorophenyl)-4-methyl-1,3-oxazol-2-yl]amino}-1,2,3,4-tetrahydronaphthalen-2-ol 
• 913295-42-8 8-(6-(4-(Trifluoromethyl)phenyl)pyrimidin-4-ylamino)-1,2,3,4-tetrahydro-naphthalen-2-ol 
• 913295-87-1 8-(4-(4-(Trifluoromethyl)phenyl)pyridin-2-ylamino)-1,2,3,4-tetrahydro-naphthalen-2-ol 
• 879609-17-3 8-({2-chloro-6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}amino)-1,2,3,4-tetrahydronaphthalen-2-ol 

Relevant articles and documents

[heteroshikuridenasetoamido[heteroshikuridenasetoamido] derivative

The present invention provides, a novel method for producing a compound represented by formula (I) and a novel method for producing a compound represented by formula (B) or a salt thereof, which are intermediates in the production of formula (I).

Discovery of dual-acting opioid ligand and TRPV1 antagonists as novel therapeutic agents for pain

In order to discover a novel type of analgesic, we investigated dual activity ligands with TRPV1 antagonism and mu-opioid receptor affinity with the goal of eliciting synergistic analgesia while avoiding the side effects associated with single targeting.

Selective Catalytic Hydrogenation of Arenols by a Well-Defined Complex of Ruthenium and Phosphorus-Nitrogen PN3-Pincer Ligand Containing a Phenanthroline Backbone

Selective catalytic hydrogenation of aromatic compounds is extremely challenging using transition-metal catalysts. Hydrogenation of arenols to substituted tetrahydronaphthols or cyclohexanols has been reported only with heterogeneous catalysts. Herein, we demonstrate the selective hydrogenation of arenols to the corresponding tetrahydronaphthols or cyclohexanols catalyzed by a phenanthroline-based PN3-ruthenium pincer catalyst.

Tetrahydro-naphthols as orally available TRPV1 inhibitors

Starting from a naphthol-based lead series with low oral bioavailability, we have identified potent TRPV1 antagonists with oral bioavailability in rats. These compounds emerged from SAR studies aimed at replacing the lead's phenol structure whilst maintai

Synthesis and biological evaluation of 5-substituted and 4,5-disubstituted-2-arylamino oxazole TRPV1 antagonists

The synthesis and structure-activity relationships of a series of 5-monosubstituted and 4,5-disubstituted 2-arylaminooxazoles as novel antagonists of the transient receptor potential vanilloid 1 (TRPV1) receptor are described. The 7-hydroxy group of the t

TRPV1 ANTAGONISTS

Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 ANTAGONISTS

Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted aromatic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions (formula (I)).

TRPV1 ANTAGONISTS

Compounds of formula (I) wherein R1, R2, R4, and W are defined in the description are TRPV 1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using

ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF

The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.